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Abstract Androgens are essential for normal prostate physiol-
ogy and are intimately associated with the growth and
progression of prostate cancer. However, few androgen regulated
genes in the prostate have been identified. Using the mRNA
differential display technique a 164-bp cDNA fragment was
identified as being androgen regulated in the human prostate.
Nucleotide sequence analysis of this fragment revealed 84%
homology with the gene encoding the cytoskeletal protein talin.
Confirmation of the androgen regulation of this gene was carried
out using Northern analysis. Primary prostatic stromal cells
treated with conditioned medium (CM) from androgen-treated
primary prostatic epithelial cells showed an approximate 2-fold
reduction in talin mRNA levels compared with stromal cells
treated with CM from epithelial cells not exposed to androgens.
Expression of talin mRNA in human prostatic tissue was
confirmed by in situ hybridisation. The highest levels of
expression were present in the epithelial cells, with lower levels
of expression in the stroma. Thus, androgen regulation of talin
expression may play a role in normal and/or aberrant growth and
development of the prostate.
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1. Introduction
Prostate cancer is the second most common cause of can-
cer-related death in American and European males, with more
than 317 000 new cases diagnosed and over 41 000 deaths
occurring every year in the USA [1]. Androgens are intimately
involved in the regulation of normal growth and di¡erentia-
tion of the prostate and therefore androgen regulated genes
are likely to contribute to the development and progression of
prostate cancer. Androgen responsive genes such as prostate
speci¢c antigen (PSA) [2] and prostate speci¢c membrane anti-
gen [3] have been characterised and PSA is commonly used as
a clinical marker for prostate cancer [4].
We have previously used the di¡erential display technique
to identify androgen responsive genes in human prostatic cells
[5]. Here we report the identi¢cation of talin as an androgen
responsive gene. Talin is a cytoskeletal protein which provides
a link between the the intracellular actin cytoskeleton and
membrane bound integrins, which mediate cell adhesion by
binding to extracellular adhesive proteins [6]. The protein is
composed of two major domains, an N-terminal domain of 47
kDa which interacts with the cell membrane, and a larger C-
terminal domain of 190 kDa which interacts with actin, vin-
culin and other cytoskeletal elements [7]. Talin is usually con-
centrated at focal contacts [8] and is likely to be important for
anchorage dependent growth. Oncogenesis is associated with
anchorage-independent growth and it is possible that talin
may play a role in this process. For instance, down-regulation
of talin using antisense technology impairs the folding and
processing of integrins and dramatically reduces the kinetics
of cell spreading [9]. Furthermore, studies on the Wistar-
Furth rat have suggested that a point mutation in the talin
gene may contribute to the high incidence of tumours in this
strain [10]. In this study we show the regulation of talin gene
expression by androgens in prostatic cells and describe the
localisation of talin mRNA in human prostatic tissue.
2. Materials and methods
2.1. Cell culture
Primary prostatic stromal and epithelial cell cultures were prepared
from tissue obtained from patients undergoing transurethral prosta-
tectomy for benign prostatic hyperplasia as previously described [11].
Approval for the use of the tissue was obtained from the local Ethical
Committee. Stromal cells were cultured in RPMI 1640 medium sup-
plemented with 10% fetal calf serum (FCS), 1% glutamine, penicillin
(100 units/ml) and streptomycin (100 Wg/ml). Epithelial cells were
cultured in WAJC 404 medium supplemented with HEPES, pH 7.6
(25 mM), sodium hydrogen carbonate (15 mM), zinc-stabilised insulin
(2.5 Wg/ml), cholera toxin (10 ng/ml), dexamethasone (1 WM), epider-
mal growth factor (10 ng/ml), 0.5% bovine pituitary extract, heparin
(4 units/ml), sodium selenite (10 ng/ml), transferrin (10 Wg/ml), pen-
icillin (100 units/ml) and streptomycin (100 Wg/ml).
For androgen exposures primary epithelial cells were washed twice
with phosphate-bu¡ered saline then exposed to RPMI medium sup-
plemented with 10% steroid depleted, dextran-coated charcoal (DCC)
treated FCS for 72 h. The cells were then incubated with DCC me-
dium or DCC medium containing 10 nM mibolerone for 0^96 h and
the culture medium was collected. Prostatic stromal cells which had
previously been exposed to DCC medium for 72 h were then incu-
bated with the collected culture medium from the epithelial cells for
96 h before harvesting and the preparation of total RNA.
2.2. Di¡erential display
Di¡erential display was performed essentially as described [12] with
the following modi¢cations. Total RNA was extracted from cells as
previously described [13]. Poly(A) RNA was puri¢ed using Dyna-
beads Oligo(dT)25 according to the manufacturer’s protocol (Dynal),
and 0.25 Wg was reverse transcribed using T12VC as primer and AMV
reverse transcriptase (400 units/ml). Di¡erential display was per-
formed in duplicate using primers T12VC and 1019 (GGTACTC-
CAC), [K-32P]dATP (500 WCi/ml) and AmpliTaq DNA polymerase
(50 units/ml). Samples were subjected to 30 cycles of PCR comprising
94‡C for 30 s, 40‡C for 20 s and 72‡C for 30 s. PCR products were
electrophoresed on 6% non-denaturing polyacrylamide gels for 20 h at
500 V. DNA from bands thought to be di¡erentially expressed was
extracted by elution into 200 Wl water and the cDNA recovered by
ethanol precipitation. Eluted cDNA species were re-ampli¢ed using
30 cycles of PCR with the appropriate primers and cloned into the
pCRII vector (Invitrogen) according to the manufacturer’s protocol.
The DNA sequences of the isolated clones were determined using the
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Thermo-Sequenase cycle sequencing kit (Amersham Life Sciences)
and homologies to known genes determined using the GenBank data-
base.
2.3. Northern blotting
RNA samples were electrophoresed as previously described [14].
Brie£y, RNA (5 Wg) was fractionated on an agarose gel, transferred
to a nylon membrane (Hybond N ; Amersham), ¢xed by heating at
80‡C for 2 h and stained with methylene blue to assess the integrity of
the RNA. Probes were generated from cloned cDNAs by restriction
endonuclease digestion and radiolabelled with [K-32P]dATP using ran-
dom-primed labelling mixture according to the manufacturer’s proto-
col (Boehringer Mannheim). Hybridisation and washing were carried
out as previously described [15]. Blots were analysed after exposure to
a phosphor storage screen using a Phosphorimager (Molecular Dy-
namics) and subsequently re-probed with radiolabelled glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) cDNA as a control for
RNA loading.
2.4. In situ hybridisation
Digoxigenin-labelled antisense and sense talin probes were gener-
ated using a 164-bp talin cDNA cloned into the pCRII vector as
template. Linearisation of the plasmid was carried out using the ap-
propriate restriction endonuclease and probes were then synthesised
using the digoxigenin labelling kit (Boehringer Mannheim) according
to the manufacturer’s protocol.
Depara⁄nised, rehydrated prostatic tissue sections (5 WM) on si-
lane-coated microscope slides were permeabilised by incubation in
proteinase K (20 Wg/ml) for 30 min at 37‡C and acetylated in PBS
containing 0.25% acetic anhydride and 0.1 M triethanolamine for
10 min at room temperature. Pre-hybridisation was carried out in
50% formamide, 4USSC, 1UDenhardt’s solution, tRNA (125 Wg/
ml) and freshly denatured salmon sperm DNA (100 Wg/ml) for
30 min at 42‡C. Hybridisation was performed using pre-hybridisation
solution containing denatured talin antisense or sense probes (5 ng per
slide) for 16 h at 42‡C. Washes were then carried out at 52‡C
(2USSC, 50% formamide, 30 min; 1USSC, 50% formamide,
30 min; 0.5USSC, 50% formamide, 30 min). The slides were then
washed in bu¡er 1 (150 mM NaCl, 100 mM Tris-HCl, pH 7.5) and
incubated in bu¡er 1 containing 5% BSA and 0.3% Triton X-100 for
30 min at room temperature. The sections were incubated in alkaline
phosphatase-conjugated antidigoxigenin antibody diluted 1:500 in
bu¡er 1 containing 5% BSA and 0.3% Triton X-100 for 2 h at
room temperature. After washing in bu¡er 1, the slides were brie£y
immersed in bu¡er 2 (100 mM NaCl, 50 mM MgCl2, 100 mM Tris-
HCl, pH 9.5) and incubated in bu¡er 2 containing 0.34 mg/ml nitro-
blue tetrazolium and 0.18 mg/ml 5-bromo-4-chloro-3-indolyl phos-
phate in the dark for 16 h at 4‡C. The slides were then immersed in
TE bu¡er, pH 8.0, rinsed in water, counterstained with Mayer’s hae-
matoxylin and mounted in Glycergel mounting medium.
3. Results
3.1. Identi¢cation of talin as an androgen responsive gene
Di¡erential display was carried out on poly(A) RNA from
primary prostatic stromal cells which had previously been in-
cubated for 96 h with conditioned medium taken from pri-
mary prostatic epithelial cells treated with 10 nM mibolerone
for 0^48 h. A representative autoradiograph using a single
primer set is shown in Fig. 1. Band patterns between individ-
ual samples were similar and bands were usually present
across all lanes. However, several bands were shown to be
reproducibly di¡erentially expressed, one of which (arrowed)
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Fig. 1. Di¡erential display was performed on poly(A) RNA from
primary prostatic cells exposed for 96 h to conditioned medium
from untreated primary prostatic epithelial cells (lane 1) or from
cells exposed to 10 nM mibolerone for 4, 8, 24 or 48 h (lanes 2^5,
respectively). A representative experiment carried out using primers
T12VC and 1019 is shown. An arrow indicates a clone that was sub-
sequently con¢rmed as di¡erentially expressed (talin).
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was down-regulated after exposure to conditioned medium
from cells treated with androgen. This band was excised
from the gel, cloned into the PCRII vector and three clones
were fully sequenced (data not shown). All three clones con-
tained a 164-bp cDNA insert with the correct £anking primer
sequences (T12VC and 1019). A search of the GenBank data-
base revealed an 84% homology with the 3P end of the murine
talin gene (Fig. 2).
3.2. E¡ect of androgen on talin mRNA levels in primary
prostatic stromal cells
To con¢rm the putative androgen regulated expression of
talin and to determine the temporal pattern of talin down-
regulation, primary prostatic stromal cells were incubated
with conditioned medium from primary prostatic cells which
had previously been treated with 10 nM mibolerone for vary-
ing lengths of time. The levels of talin mRNA were then
assessed using Northern analysis. A probe was designed for
human talin using sequence information from a series of ESTs
with high homology to the murine talin gene. An 833-bp
cDNA was ampli¢ed using RT-PCR and the identity con-
¢rmed by sequencing. This probe identi¢ed an 8.5-kb
mRNA by Northern analysis similar to the 8.3-kb mRNA
for murine talin [16]. Talin mRNA levels were shown to be
decreased to approximately 50% of control levels following
exposure to conditioned medium from primary epithelial cells
exposed to 10 nM mibolerone for 96 h (Fig. 3).
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Fig. 3. Northern analysis was performed using total RNA from pri-
mary prostatic stromal cells exposed for 96 h to conditioned me-
dium from untreated primary epithelial cells or from cells exposed
to 10 nM mibolerone for the times indicated. Blots were probed
with a talin cDNA then stripped and reprobed with a GAPDH
cDNA as a control for gel loading. The expression of talin was nor-
malised to GAPDH and the expression relative to untreated control
cells was calculated. Results are expressed as mean þ S.D. (n = 3).
Fig. 2. Nucleotide sequence of di¡erentially expressed clone 9308
and homology with the 3P region of murine talin cDNA. Vertical
lines represent identical bases, £anking primer sequences (1019 and
T12VC) are in boldface and the putative polyadenylation signal is
underlined.
Fig. 4. In situ hybridisation was carried out using digoxigenin-labelled antisense (A) or sense (B) riboprobes on sections of benign prostatic tis-
sue. Talin mRNA, denoted by a purple-blue colouration, was present in epithelium (e) and at lower levels in the stroma (s).
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3.3. In situ hybridisation
Hybridisation of digoxigenin-labelled riboprobes to talin
mRNA in representative sections of benign prostatic tissue
is shown in Fig. 4. The antisense probe hybridised strongly
to prostatic epithelial cells, the strongest expression being con-
¢ned to the basal cells, with the surrounding stroma showing
lower levels of expression. No signal was detectable when
sections were hybridised with the corresponding sense probe.
4. Discussion
In the present study we have identi¢ed a gene in cultured
human prostatic stromal cells that is down-regulated by the
addition of conditioned medium (CM) from prostatic epithe-
lial cells treated by androgens which was not a¡ected by CM
from epithelial cells not treated with androgens. We identi¢ed
this gene by means of the di¡erential display technique and
con¢rmed its expression in human prostatic tissue by in situ
hybridisation.
We have modelled stromal-epithelial interactions in the
human prostate by exposing one prostatic cell type to con-
ditioned medium from another. Similar methods have previ-
ously been used to show stimulated LNCaP cell proliferation
when treated with conditioned medium from prostatic and
bone ¢broblasts [17]. In our study, talin mRNA expression
was found to be decreased in primary prostatic stromal cells
in response to an exposure to conditioned medium from an-
drogen treated epithelial cells. Direct exposure of stromal cells
to androgen had negligible e¡ect on talin expression (result
not shown) and therefore this suggests that the action of an-
drogens on talin expression in prostatic stromal cells can be
mediated indirectly by a secreted factor produced by prostatic
epithelial cells ; a paracrine factor(s) produced by prostatic
epithelial cells is the likely agent of this androgen-mediated
down-regulation. It is true, however, that androgen is still
present in the conditioned medium and it is possible that
the changes in talin expression seen are the result of paracrine
factors acting in synergy with androgen. The kinetics of
down-regulation suggest that the action of androgen is rela-
tively slow. For instance, the most signi¢cant decrease in talin
expression is after treatment of cells with conditioned medium
from cells incubated with androgen for 96 h. However, genes
such as nm23, c-myc or EGRK show a 2^4-fold change in
expression after direct exposure to androgen within 6^8 h
[18,19]. Similar kinetics of expression to those seen with talin
have been previously reported for orphan receptor TR2 and
the cDNA tag TL35 [20,21].
Recent research has implicated the regulation of expression
of cell adhesion molecules and cytoskeletal proteins as a key
factor in the progression of cancer. For example, reduced or
aberrant expression of E-cadherin and K-catenin are predic-
tors of poor outcome in prostate cancer [22]. In addition, the
actin-¢lament binding protein gene, TMe1, identi¢ed using
di¡erential display, is down-regulated in prostate cancer
when compared to the normal prostate [23]. Although little
is known about the human talin gene, it has been localised to
chromosome 9p [24] and deletions on this chromosome in
primary untreated prostate cancers have been reported [25].
Furthermore, studies on di¡erential gene expression between
normal muscle and rhabdomyosarcoma identi¢ed reduced or
absent talin mRNA levels in tumour cells compared with nor-
mal cells [26]. Also, in invasive breast carcinoma, down-regu-
lation of talin and other cytoplasmic components of focal
contacts such as K-catenin, vinculin, K-actinin and pp125 (fo-
cal adhesion kinase) has been demonstrated [27]. We have
shown that androgen mediates a down-regulation in talin ex-
pression in prostatic stromal cells. There have been no pre-
vious reports on the regulation of talin by androgens; how-
ever, androgen regulation of other cytoskeletal proteins has
been demonstrated in rat motoneurons [28]. Furthermore, sex
hormone regulation of talin expression has been demonstrated
previously in a study in which estradiol was shown to decrease
both the overall number and size of talin- and vinculin-rich
cell-matrix adhesion plaques in MCF-7 human mammary car-
cinoma cells [29]. The androgen-mediated reduction in talin
gene expression that we have observed in primary prostatic
stromal cells could form part of a mechanism leading to loss
of cell adhesion in epithelial cells mediated through androgen
action. Our in situ hybridisation studies show that talin
mRNA is not only expressed in the stroma of prostatic tissue
sections but also at higher levels in the epithelial cells. It is
possible, therefore, that talin expression in these cells may also
play an important role in the regulation of cell adhesion in
both benign and malignant prostate.
Further studies on talin expression in benign and malignant
prostate will be required to further delineate its possible role
in the development and progression of prostatic disease.
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